PFCS
KLRS

Pale Fire Capital SE’s Kalaris Therapeutics KLRS Stock Holding History

Pale Fire Capital SE’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
+39,626
New +$206K 0.01% 67

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pale Fire Capital SE's KLRS Position: Q2 2026 in Review

Pale Fire Capital SE opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 39,626 shares worth $161K. The stake represents 0.01% of the portfolio and ranks #67 among its holdings.

57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Pale Fire Capital SE held 39,626 shares of Kalaris Therapeutics worth $161K as of Q2 2026.
  • Kalaris Therapeutics was a new Pale Fire Capital SE position in Q2 2026.
  • Kalaris Therapeutics made up 0.01% of Pale Fire Capital SE's portfolio in Q2 2026, its #67 holding.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.